

**In the Claims:**

Please amend the claims by replacing all prior versions of the claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:

1. (Currently Amended) A composition in the form of an emulsion consisting essentially of:
  - (a) a therapeutically effective amount of a pharmaceutical agent;
  - (b) an amount of ~~a fish oil~~ an  $\Omega$ -3 triglyceride predetermined so as to deliver the pharmaceutical agent to a predefined tissue in a subject; and
  - (c) an amount of an emulsifier sufficient to result in the composition forming the emulsion,  
wherein more than 80% of the particles in the emulsion have a diameter between 30 and 150 nm.
2. (Currently Canceled).
3. (Currently Amended) The composition of claim 3 ~~2~~, wherein the predefined tissue is an extrahepatic tissue and the  $\Omega$ -3 triglyceride effects delivery of the pharmaceutical agent to the extrahepatic tissue.
4. (Previously Canceled)
5. (Previously Canceled)
6. (Previously Canceled)
7. (Previously Canceled)
8. (Previously Canceled)

9. (Previously Canceled)
10. (Currently Canceled)
11. (Currently Canceled)
12. (Currently Canceled)
13. (Currently Canceled)
14. (Currently Canceled)
15. (Currently Amended) A composition in the form of an emulsion ~~comprising~~ consisting essentially of:
  - (a) a therapeutically effective amount of a pharmaceutical agent;
  - (b) an amount of a triglyceride;
  - (c) an amount of an emulsifier sufficient to result in the composition forming the emulsion; and
  - (d) an amount of a ligand which specifically binds to a predefined tissue;wherein more than 80% of the particles in the emulsion have a diameter between 30 and 150 nm and wherein the amount of the triglyceride is predetermined to deliver the pharmaceutical agent to the predefined tissue, and the amount of ligand effects the delivery of the pharmaceutical agent to the predefined tissue.
16. (Original) The composition of claim 15, wherein the ligand is an apolipoprotein E.
17. (Original) The composition of claim 16, wherein the apolipoprotein E is human apolipoprotein E or a homolog

thereof differing by fewer than 3 amino acids, but having the biological activity of naturally occurring human apolipoprotein E.

18. (Currently Canceled)
19. (Currently Canceled)
20. (Currently Canceled)
21. (Currently Canceled)
22. (Currently Canceled)
23. (Currently Canceled)
24. (Currently Amended) A composition in the form of an emulsion consisting essentially of:
  - (a) a therapeutically effective amount of a therapeutically effective amount of a pharmaceutical agent;
  - (b) an amount of a medium-chain triglyceride and/or a long-chain triglyceride;
  - (c) an amount of an emulsifier sufficient to result in the composition forming the emulsion;

wherein more than 80% of the particles in the emulsion have a diameter between 30 and 150 nm and wherein the amount of the triglyceride is predetermined so as to deliver the pharmaceutical agent to a predefined tissue in a subject.
25. (Currently Canceled)
26. (Currently Canceled)

Applicants: Richard Deckelbaum et al.  
U.S. Serial No.: 10/033,629  
Filed: December 28, 2001  
Page 5

27. (Currently Canceled)

28. (Currently Canceled)

29. (Currently Canceled)

30. (Currently Canceled)